Antoine Bejjani
Overview
Explore the profile of Antoine Bejjani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scimeca G, Krishnathasan D, Rashedi S, Lan Z, Sato A, Hamade N, et al.
J Thromb Thrombolysis
. 2025 Mar;
PMID: 40064840
COVID-19 is associated with an increased risk of venous thromboembolism (VTE) in hospitalized patients. Although prior studies have attempted to identify predictors of VTE, restricted sample size and use of...
2.
Rashedi S, Bejjani A, Hunsaker A, Aghayev A, Khairani C, McGonagle B, et al.
Thromb Res
. 2025 Jan;
247:109271.
PMID: 39862754
Background: Isolated subsegmental pulmonary embolism (issPE) is a commonly encountered diagnosis. Although the International Classification of Diseases (ICD)-10 codes are used for research, their validity for identifying issPE is unknown....
3.
Bejjani A, Bikdeli B
Thromb Haemost
. 2024 Nov;
PMID: 39557062
Direct oral anticoagulants (DOACs) have transformed the landscape of antithrombotic therapy in the past two decades. However, there is uncertainty about when they should or should not be used for...
4.
Bikdeli B, Khairani C, Bejjani A, Lo Y, Mahajan S, Caraballo C, et al.
J Thromb Haemost
. 2024 Nov;
23(2):556-564.
PMID: 39505153
Background: Many research investigations for pulmonary embolism (PE) rely on the International Classification of Diseases 10th Revision (ICD-10) codes for analyses of electronic databases. The validity of ICD-10 codes in...
5.
Khairani C, Bejjani A, Bikdeli B
Br J Haematol
. 2024 Sep;
205(5):2080-2081.
PMID: 39344485
No abstract available.
6.
Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use
Khairani C, Bejjani A, Assi A, Porio N, Talasaz A, Piazza G, et al.
Res Pract Thromb Haemost
. 2024 May;
8(4):102424.
PMID: 38812988
Direct oral anticoagulants (DOACs) have become the preferred option for treatment of venous thromboembolism due to their favorable profile compared with other agents such as vitamin K antagonists or low-molecular-weight...
7.
Low absolute risk of thrombotic and cardiovascular events in outpatient pregnant women with COVID-19
Bikdeli B, Krishnathasan D, Khairani C, Bejjani A, Davies J, Porio N, et al.
Thromb Res
. 2024 Apr;
237:209-215.
PMID: 38677791
Introduction: Pregnancy may contribute to an excess risk of thrombotic or cardiovascular events. COVID-19 increases the risk of these events, although the risk is relatively limited among outpatients. We sought...
8.
Bejjani A, Khairani C, Assi A, Piazza G, Sadeghipour P, Talasaz A, et al.
J Am Coll Cardiol
. 2024 Jan;
83(3):444-465.
PMID: 38233019
For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism treatment. However, randomized controlled trials suggest that...
9.
Bikdeli B, Sadeghipour P, Lou J, Bejjani A, Khairani C, Rashedi S, et al.
Semin Thromb Hemost
. 2024 Jan;
50(6):851-865.
PMID: 38176425
The inferior vena cava (IVC) and superior vena cava are the main conduits of the systemic venous circulation into the right atrium. Developmental or procedural interruptions of vena cava might...
10.
Bikdeli B, Khairani C, Krishnathasan D, Bejjani A, Armero A, Tristani A, et al.
Thromb Res
. 2023 Jun;
228:94-104.
PMID: 37302267
Background: Coronavirus disease 2019 (COVID-19) is associated with excess risk of cardiovascular and thrombotic events in the early post-infection period and during convalescence. Despite the progress in our understanding of...